Lilly rides Mounjaro, Zepbound to better
Time:2024-05-22 11:09:22 Source:entertainmentViews(143)
Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Previous:South Carolina governor vetoes bills to erase criminal history in gun and bad check cases
Next:Trump visits Minnesota after son Barron's Florida high school graduation
You may also like
- How major US stock indexes fared Monday, 5/20/2024
- Guardians acquire right
- Lawyers for Larry Nassar assault survivors reach $100M deal with DOJ, source says
- Regulators pleased Union Pacific is using fewer temporary shipping limits
- Closing prices for crude oil, gold and other commodities
- Kentucky spokeswoman: School is 'distressed' to hear of alleged sexual misconduct by ex
- US reimposes oil sanctions on Venezuela ahead of election
- PGA Championship to return to Kiawah Island in 2031
- France hits go